

Laufende Klinische Studien

Diagnosis	Study Title	Study Name / Product /Implimentation	Sponsor	PI	Co- Investigator	Status / Start / End
Prof. Dr. Dagmar Simon						
Atopische Dermatitis	M23-696	A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Dermatitis (Level-Up)	abbvie	Prof. Simon		recruiting
Atopische Dermatitis	AMG451 Protokoll 20210144 ROCKET-SHUTTLE	A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)	Amgen	Prof. Simon		recruiting
Atopische Dermatitis	AMG451 Extension Protokoll 20210146 ROCKET ASCEND	A Phase 3, 104 weeks, Multicenter, Double-Blind Maintenance Study to Assess Long-term Safety , Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (ROCKET-ASCEND)	Amgen	Prof. Simon		in Planung
Chronic Inducible Urticaria	LOU064 Extension A2302	A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to asses the efficacy, safety and tolerabilit of Remibrutinib (LOU064) in aduld chronic spontaneous urticaria patients who completed the preceding remicrutinib Phase 3 studies	Novartis	Prof. Simon		recruiting
Urticaria	LOU064 A2303B	A multicenter, randomized, double-blind, placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in aduld chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines	Novartis	Prof. Simon		recruiting
Atopische Dermatitis	TREAT	Treatment and medical care of patients with moderate-to-severe atopic dermatitis - Swiss national clinical registry TREAT Switzerland	Sanofi	Prof. Simon		recruiting

Dermatologische Klinik Inselspital Bern Studienübersicht

Hypereosinophilic Syndrome (HES)	NATRON D3254C00001	A Multicentre, Randomized, Double-blind, Parallel-group, Placebo-Controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with HES	AstraZeneca	Prof. Simon	Dr. C. Bürgler	recruiting
Prof. Dr. Robert Hunger						
Hidradenitis suppurativa	BI Trail 1368-0098	Randomized, double-blind, placebo-controlled, Phase II b / Phase III study to evaluate the efficacy and safety of Spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.	Boehring Ingelheim	Prof. Hunger		in Planung
Advanced Cutaneous Squamous Cell Carcinoma	CemiSkin	Nichtinterventionelle multizentrische, longitudinale 2-Kohorten Studie zur Wirksamkeit, Sicherheit und Quality of Life (QoL) bei Patienten mit fortgeschrittenem kutanen Plattenepithelkarzinom (adCSCC, Advanced Cutaneous Squamous Cell Carcinoma), die mit Cemiplimab (prospektive Kohorte) oder anderen Therapieansätzen behandelt werden	Sanofi-Aventis	Prof. Hunger	Dr. Benzaquin	recruiting
Melanoma	NEO-DREAM	An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L191L2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients	Philochem	Prof. Hunger		recruiting
Melanoma	BERING_MELANOMA	Encorafenib + Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma; a multi-centric, national, prospective, longitudinal, non-interventional study in Switzerland Binimetinib plus Encorafenib Real life Investigation of Next Generation Melanoma treatment	Pierre Fabre Pharma AG/Alcedis	Prof. Hunger	Dr. Lamos Dr. Bossart	recruiting
Basal cell carcinoma	NISSO	A non-interventional, multi-national, multi-center post-authorization safety study (PASS) to assess the long-term safety and tolerability of Odomzo® (Sonidegib) administered in patients with locally advanced basal cell carcinoma (laBCC) - NISSO	Sun Pharmaceutical Industries Europe B.V.	Prof. Hunger		recruiting
Prof. Dr. Nikhil Yawalkar						
Psoriasis (GPP)	SPESOLIMAB (Compassionate Use Program)	Open label expanded access program (EAP) or compassionate use program (CUP) or named patient use (NPU) of intravenous Spesolimab 900 mg in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare	Boehring Ingelheim	Prof. Yawalkar / K. Heidemeyer	Dr. Heidemeyer	recruiting

Dermatologische Klinik Inselspital Bern Studienübersicht

Psoriasis vulgaris	SDNTT	Psoriasis Register-Studie / Long-Term Benefits of Systemic Psoriasis Therapy	SGDV & Uni Zürich	Prof. Yawalkar	diverse Ärzte siehe separate Liste	recruiting
Weitere						
Chronic Pruritus	CP-derma1	Multicenter case-control study on risk factors for generalised chronic pruritus , with focus on patients' comorbidities and medications intake		Dr. Cazzaniga	Dr. Benzaquen	recruiting